Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J is the fourth drugmaker backed by the Trump's administration's Covid-19 vaccine program Operation Warp Speed to enter late-stage testing.

Johnson & Johnson enters late-stage trial testing its coronavirus vaccine

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch...

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

Genmab - ADR

Shares in Danish biotech firm Genmab fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson over royalty payments for its key cancer drug.

Genmab shares drop on legal battle with J&J over cancer drug

Broadcom

CVS Health

Home Depot

Medical Properties Trust

CNBC used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts, like Home Depot and Johnson & Johnson.

Wall Street's best performing analysts have a strong buy rating on these 6 dividend stocks

AstraZeneca

Pfizer

You don't have to take on a huge amount of risk to profit from these solid COVID-19 vaccine leaders.

3 Best Coronavirus Vaccine Stocks to Buy Right Now

Apple

Disney

DraftKings

PayPal

Starbucks

Buying and holding long-term stocks is not as popular as zero commission trading in 2020, but it remains the best way to make money in the market.
The post 6 Long-Term Stocks to See You Through the Bad Times appeared first on InvestorPlace.

6 Long-Term Stocks to See You Through the Bad Times

Automatic Data Processing

Walmart

Not all stocks are subject to market-wide weakness, as their underlying companies are reliably resilient.

These 3 Dividend Aristocrats Will Shield You From Another Market Crash

Abbott Labs

The company is using cutting-edge data science to push the boundaries of diagnostics.  What's more, you can buy 20/20 GeneSystems stock through an equity crowdfunding campaign.

20/20 GeneSystems Stock: Leveraging AI for More Accurate Cancer Screening

New York Governor Andrew Cuomo on Thursday announced the state has filed civil charges against Johnson & Johnson (NYSE: JNJ), accusing it of insurance fraud in connection with understating the risks posed by opioid drugs to doctors and elderly patients.

Johnson & Johnson Downplayed Opioid Drugs' Side Effects, New York Unveils Charges

The healthcare giant is being charged with insurance fraud.

New York Files Charges Against Johnson & Johnson Over Opioid Marketing

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.

NY charges Johnson & Johnson with fraud over opioid claims

Johnson & Johnson: For The Very Young To The Very Old

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

New York charges Johnson & Johnson with insurance fraud over opioid claims

AbbVie

Carlisle Companies

Coca-Cola

Skyworks Solutions

Juicy dividends or explosive growth stocks? Most investors don't want to choose.

6 Dividend Stocks To Buy For Stable Yield And Growth Potential

Morgan Stanley

Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

These stocks have what you want during turbulent times: solid business models, stable cash flows, and reliable dividends.

3 Steady Stocks to Buy in a Highly Volatile Market

Infinite Looks, Inc., founder Keenan Beasley wants to help Black women who love working out hit the gym without worrying about "sweating out their edges."

Why Johnson & Johnson and others are investing in this burgeoning Black-owned haircare company

Atara Biotherapeutics

American Express

Fiverr

JPMorgan Chase & Co

Merck

NIKE

Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

CureVac B.V

GlaxoSmithKline

Inovio Pharmaceuticals

Moderna

Novavax

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. 
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

Q2 is seen by company's management as the worst quarter as the things started to improve at the end of the quarter.

Johnson & Johnson: Pick It In The Absence Of News

BioNTech SE

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

Companies could only distribute the vaccine internationally if domestic need is met.

Senate Considers Bill to Block International Distribution of Coronavirus Vaccine

J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.

J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis

Amgen

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

News for Johnson & Johnson Stock (JNJ)